Because it is not clear how the pharmacokinetics and dynamics are affected in the morbidly obese patient, this study is performed in order to develop a population pharmacokinetic and pharmacodynamic model of Propofol when used for induction and maintenance of anaesthesia in the morbidly obese patient (BMI > 40).